New "rescue" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Hsieh.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
DNA vaccination with the plasmid expressing Japanese encephalitis virus (JEV) nonstructural protein 1 (pJNS1) has been shown to induce effective immunity against JEV infection. To further increase the efficacy of pJNS1 DNA vaccination, we coinjected pJNS1 with a plasmid that expresses heat shock protein 70.1 (pHSP70.1) into mice. We found that coinjection of pHSP70.1 enhanced both T cell proliferation and cytotoxic effects, but not the antibody response to JEV. Moreover, mice immunized with both pHSP70.1 and pJNS1 were resistant to lethal challenges of JEV, indicating that the protective immunity against JEV is not decreased, in spite of the low antibody titer via the immunization of pHSP70.1. Since DNA vaccination administered by pJNS1 did not elicit strong cellular immunity in our previous study, the administration of pHSP70.1 apparently could be used as an adjuvant to enhance cell-mediated immunity in this model system. Thus, coadministration of pHSP70.1 DNA with plasmid DNA encoding tumor- or virus-specific antigens might be very useful in the treatment of cancers and other infectious diseases.
This study examines the relationship between pre-, during-, post-treatment variables, and treatment outcome by using a secondary data analysis of the 6- and 12-months posttreatment follow-up data from 2,317 adolescent subjects. Pre-treatment variables included in this study are psychosocial, family-related, substance abuse, and special event variables. During-treatment variables are length of stay and parental participation in treatment. Post-treatment variables cover the attendance of subsequent treatment/continuing care, such as AA/NA and CD aftercare, and parental attendance of subsequent treatment. Results from discriminant function analyses indicated that during- and post-treatment variables could differentiate the abstinence status at 6- and 12-month follow-ups. It was also shown that the post-treatment variable group exhibited the best classification accuracy among the three variable groups across both follow-up periods. Limitations in applying research findings and their implications for adolescent substance abuse treatment are also discussed.